Clinical Development
Clinical Pipeline
KINASE INHIBITION
Sorafenib
Liver Cancer
Unresectable
STORM – Adjuvant
Kidney Cancer
Advanced
SORCE/ASSURE – Adjuvant
Thyroid Cancer
DECISION – Monotherapy
Breast Cancer
RESILIENCE – Capecitabine +/-
Regorafenib
COLORECTAL CANCER
Advanced
GIST
Advanced
LIVER CANCER
Second-line post Nexavar
COLORECTAL CANCER
Following Resection of Liver Metastases
PROTEASOME INHIBITION
Carfilzomib
Multiple Myeloma
Advanced myeloma, monotherapy
FOCUS – Relapsed and refractory, monotherapy vs. BSC2
ASPIRE – Relapsed, +/- lenalidomide/dexamethasone
ENDEAVOR-Relapsed, vs. bortezomib + dexamethasone
CLARION - Front-line, vs. bortezomib + melphalan + prednisone
Oprozomib
Hematologic Malignancies
Monotherapy
Solid Tumor
Monotherapy
ONYX 0914 (immunoproteasome inhibitor)
Preclinical
Palbociclib (PD-991)3
Advanced breast cancer
1 Stivarga® (regorafenib) is a Bayer compound being developed by Bayer. Onyx receives a 20% royalty on all global net sales in approved markets. Bayer and Onyx are jointly promoting Stivarga in the U.S.
2 Best supportive care
3 Palbociclib is a Pfizer compound being developed by Pfizer. If approved, Onyx will receive an 8% royalty on global net sales.